Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,883.14
    +534.95 (+1.04%)
     

  • CMC Crypto 200

    1,373.06
    +60.44 (+4.60%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.25
    +0.52 (+0.63%)
     

  • GOLD FUTURES

    2,405.70
    +7.70 (+0.32%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA

Zacks Equity Research
Updated

Allergan plc AGN announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, ulipristal acetate. Allergan is looking to get ulipristal acetate approved for the treatment of abnormal uterine bleeding from fibroids in that organ. The company expects the FDA to give its decision in the first half of 2018. Once approved, ulipristal acetate will be the first once-daily non-surgical oral treatment option approved for the condition.

Allergan’s shares have declined 1.2% compared with the industry’s decline of 20.4%.

 

There are other companies that have pipeline candidates being evaluated for uterine fibroids. In July 2017, Bayer Aktiengesellschaft BAYRY is evaluating vilaprisan in women suffering from uterine fibroids and in July initiated a phase III study ASTEROID for the same.

ADVERTISEMENT

AbbVie Inc. ABBV along with Neurocrine Biosciences, Inc. is evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids. In April this year, the companies announced positive results from a phase IIb study which showed that elagolix met its primary endpoint by significantly reducing the number of heavy bleeding days rapidly within the assessment period of six months from the baseline in comparison to a placebo, utilizing the alkaline hematin method.

Allergan PLC. Price

Allergan PLC. Price | Allergan PLC. Quote

 

Zacks Rank & Stock to Consider

Currently, Allergan carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is ACADIA Pharmaceuticals Inc ACAD carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Over the last 60 days, ACADIA’s loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018. The company delivered positive earnings surprises in two of the trailing four quarters, with an average beat of 7.97%. Year to date, the share price of the company has climbed 27.9%.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Allergan PLC. (AGN) : Free Stock Analysis Report
 
AbbVie Inc. (ABBV) : Free Stock Analysis Report
 
Bayer AG (BAYRY) : Free Stock Analysis Report
 
ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research